

Docket No. 1795/52241-EB/JPW/P3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICER CL

JAN 3 0 2003

Applicants

Jonathan A. Bard et al.

U.S. Serial No. :

10/006,343

TECH CENTER 1600/2900

Filed

December 3, 2001

For

DNA ENCODING GALANIN GALR3 RECEPTORS AND

USES THEREOF

1185 Avenue of the Americas New York, New York 10036

January 22, 2003

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. \$1.97(c)(1) and \$1.97(e)(1) to supplement the Information Disclosure Statement filed on December 3, 2001.

According to 37 C.F.R. \$1.97(c), an Information Disclosure Statement shall be considered by the U.S. Patent and Trademark Office if filed before the mailing date of a Final Office Action under C.F.R. \$1.113, a Notice of Allowance under 37 C.F.R. \$1.311, or other Office Actions which close prosecution in the application, provided that the Statement is accompanied by either (1) the statement specified in 37 C.F.R. §1.97(e) or (2) the fee as set forth in C.F.R. \$1.17(p). Pursuant to \$1.97(e)(1), applicants hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication

Applicants: Jonathan A. Bard, et al.

U.S. Serial No.: 10/006,343

Filed: December 3, 2001

Page 2

from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Specifically, each item of information Disclosure Statement. contained in this Information Disclosure Statement was first cited in a Supplementary Partial European Search Report issued October 24, 2002 in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants direct the Examiner's attention to the disclosures which are listed on the attached Form PTO-1449 (Exhibit 1), and attached hereto as Exhibits 2-3:

- 1. Branchek, et al., "Galanin Receptor Subtypes," Trends In Pharmacological Sciences, Elsevier Trends Journal. (March 2000) **21**(3): 109-116 (**Exhibit 2**); and
- 2. Smith, et al., "Cloned Human and Rat Galanin GALR3 Receptors," The Journal of Biological Chemistry. (September 1998) 273 (36): 23321-23326 (Exhibit 3).

The above-listed references were first cited in a Supplementary Partial European Search Report issued October 24, connection with EP 97 91 0850, a foreign counterpart of the subject application. A copy of this search report is attached hereto as Exhibit A. Since three months from October 24, 2002 is <u>January 24</u>, 2003, this Supplemental Information Disclosure Statement is being timely filed.

Applicants: Jonathan A. Bard, et al.

U.S. Serial No.: 10/006,343

Filed: December 3, 2001

Page 3

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplementary Information Disclosure Statement pursuant to 37 C.F.R. \$1.97(c)(1) and 1.97(e)(1). However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

John P. White

Date

Reg. No. 28,678

John P. White Registration No. 28,678 Attorney for Applicants Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036 (212) 278-0400

		(0)) 	AH 28	Mer	Separate Sep				Sheet	<u>1</u> of	1_
Form PTO-1449 Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									Atty. Doc 1795/52	Seria	l No.	
									Applicants Jonathan A. Bard, et al			
									Filing Dat Decemb	Group		
							U.S. PA	TENT DOCUMEN	NTS			
Examiner Initial		Document Number					Date Name		Class			g Date propriate
		ļ	<u> </u>	\sqcup	4-	_	ļ. <u> </u>	ļ		ļ	<u> </u>	
		_	ļ				<u> </u>				<u> </u>	
	_					\perp	·			FOF	WE	D
						$oldsymbol{\perp}$				REUL		
										RECE JAN 3	b so	U3
						Ţ					rp 1	B00/290
										JAN 3	Eu	
			•	I II		F	OREIGN	PATENT DOCUM	IENTS	1. 1. 2.		
	Document Number						Date	Country	Class	Subclass	Translation	
											Yes	No
					T	T^-					1	
	-				+	†	<u> </u>	 				
	_				+-	+-					1	
	+	-	 		+	+-				 	 	:
		L						li A (I Fi/I B			لـــــــــــــــــــــــــــــــــــــ	
		anc	hek	, et a	1., "(Gala	nin Recept	ding Author, Title, Dat for Subtypes," <i>Trend</i> 1(3): 109-116 (Exh	ds In Pharn	acological Scien	ces, E	Elsevier
								l Rat Galanin GALI 3(36): 23321-23326			of Bio	logical
	-											
												
							 		- 			
1												

DATE CONSIDERED

EXAMINER

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Jonathan A. Bard, et al. U.S. Serial No: 10/006,343

Filed: December 3, 2001

Exhibit 1